

Boston Scientific

## **Boston Scientific Announces Financial Outlook for 2007**

PRNewswire-FirstCall

NATICK, Mass.

(NYSE:BSX)

NATICK, Mass., Nov. 6 /[PRNewswire-FirstCall](#)/ -- At a meeting with analysts today, Boston Scientific Corporation (NYSE: BSX) provided its financial outlook for 2007. Sales goals for 2007 range between \$8.65 billion and \$9.45 billion, an increase of 11 percent to 21 percent from estimated 2006 sales on a reported basis. Worldwide sales of TAXUS® paclitaxel-eluting coronary stent systems are expected to range between \$2.26 billion and \$2.70 billion for 2007. U.S. sales of TAXUS coronary stent systems for 2007 are expected to range between \$1.45 billion and \$1.75 billion. Worldwide cardiac rhythm management sales for 2007 are expected to range between \$1.96 billion and \$2.23 billion, of which \$1.30 billion and \$1.49 billion are expected to be in the U.S. Boston Scientific has targeted double-digit growth of both 2007 sales and earnings compared to estimated 2006 on a reported basis, as well as 2007 operating cash flow in excess of \$1 billion.

A replay of the webcast of today's analyst meeting will be archived and available in the Investor Relations section of the Company's website beginning no later than 2:30 p.m. ET on Monday, November 6.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit:

<http://www.bostonscientific.com/>.

This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, integration of acquired companies, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.

**CONTACT:**

Dan Brennan  
508-650-8538 (office)  
617-459-2703 (mobile)  
Investor Relations  
Boston Scientific Corporation

Paul Donovan  
508-650-8541 (office)  
508-667-5165 (mobile)  
Media Relations  
Boston Scientific Corporation

**SOURCE:** Boston Scientific Corporation

**CONTACT:** Dan Brennan, Investor Relations, +1-508-650-8538, mobile: +1-617-459-2703; or Paul Donovan, Media Relations, +1-508-650-8541, mobile: +1-508-667-5165, both of Boston Scientific Corporation

Web site: <http://www.bostonscientific.com/>

---

<https://news.bostonscientific.com/news-releases?item=58913>